amlodipine has been researched along with Angina Pectoris with Normal Coronary Arteriogram in 2 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Excerpt | Relevance | Reference |
---|---|---|
"Only atenolol was found to significantly improve chest pain episodes, suggesting that it should be the preferred drug when starting pharmacologic treatment of patients with syndrome X." | 2.69 | Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. ( Colonna, G; Lanza, GA; Maseri, A; Pasceri, V, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sharman, JE | 1 |
Lim, R | 1 |
Marwick, TH | 1 |
Lanza, GA | 1 |
Colonna, G | 1 |
Pasceri, V | 1 |
Maseri, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106] | 37 participants (Actual) | Interventional | 1999-12-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline
Intervention | percentage of pre-stimulus diameter (Mean) |
---|---|
Hormone Replacement Therapy | 8.2 |
Placebo | 8.8 |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks
Intervention | percentage of pre-stimulus diameter (Mean) |
---|---|
Hormone Replacement Therapy | 8.8 |
Placebo | 7.3 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks
Intervention | percent change in PCR/ATP ratio (Mean) |
---|---|
Hormone Replacement Therapy | -7.7 |
Placebo | 1.1 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline
Intervention | percent changed in PCR/ATP ratio (Mean) |
---|---|
Hormone Replacement Therapy | -13.8 |
Placebo | -7.0 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline
Intervention | mm (Mean) |
---|---|
Hormone Replacement Therapy | -0.79 |
Placebo | -0.79 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.8 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 5.4 |
Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks
Intervention | metabolism equivalents (Mean) |
---|---|
Hormone Replacement Therapy | 6.1 |
Placebo | 5.4 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)
Intervention | mm (Mean) |
---|---|
Hormone Replacement Therapy | -1.05 |
Placebo | -0.63 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
Hormone Replacement Therapy | 59.4 | 58.8 | 76.5 | 54.5 | 55.2 | 66.4 | 35.6 | 59.4 |
Placebo | 44.4 | 25.0 | 66.7 | 41.5 | 57.2 | 69.3 | 41.2 | 56.1 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
Hormone Replacement Therapy | 60.8 | 54.2 | 70.3 | 53.3 | 55.4 | 66.7 | 35.6 | 59.4 |
Placebo | 43.8 | 37.3 | 66.7 | 42.1 | 57.4 | 65.7 | 42.9 | 53.2 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks
Intervention | percent of participants (Number) | ||||
---|---|---|---|---|---|
Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
Hormone Replacement Therapy | 41 | 59 | 35 | 35 | 24 |
Placebo | 89 | 78 | 67 | 67 | 56 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline
Intervention | percent of participants (Number) | ||||
---|---|---|---|---|---|
Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
Hormone Replacement Therapy | 89 | 76 | 50 | 44 | 39 |
Placebo | 68 | 53 | 37 | 58 | 37 |
1 trial available for amlodipine and Angina Pectoris with Normal Coronary Arteriogram
Article | Year |
---|---|
Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X.
Topics: Adrenergic beta-Antagonists; Amlodipine; Analysis of Variance; Atenolol; Cross-Over Studies; Double- | 1999 |
1 other study available for amlodipine and Angina Pectoris with Normal Coronary Arteriogram
Article | Year |
---|---|
Cardiac syndrome X: relevance of arterial pressure waveform analysis to patients with chest pain and normal coronary arteries.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chest Pain; Coronary Angiography; Coronary Circulation; E | 2006 |